Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Aug 29, 2019 (7 years ago)

Oxaliplatin Active Pharmaceutical Ingredient

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

cGMP Deviations: Potential glass contamination

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Oxaliplatin Active Pharmaceutical Ingredient, Johnson Matthey Pharmaceutical Materials 2003 Nolte Drive, West Deptford, NJ 08066-1742 (856) 384-7001, NDC 49821-0075-XX

Affected NDC 49821-0075

Compare with the code on your package — it is the most precise check available.

Drug: Oxaliplatin

Recalling firm
Johnson Matthey Inc.
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1882-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Oxaliplatin recalls

See all
Class II · Moderate risk

Eloxatin (OXALIplatin injection)

CGMP Deviations: Eloxatin was manufactured by Ben Venue Laboratories, a contract manufacturer, which was recently inspected by the agency and revealed significant issues in Good Manufacturing Practices.

Terminated cGMP deviation sanofi-aventis US, Inc. NDC 0024-0591-20 D-1408-2012
Class II · Moderate risk

Eloxatin (OXALIplatin injection)

CGMP Deviations: Eloxatin was manufactured by Ben Venue Laboratories, a contract manufacturer, which was recently inspected by the agency and revealed significant issues in Good Manufacturing Practices.

Terminated cGMP deviation sanofi-aventis US, Inc. NDC 0024-0590-10 D-1407-2012

Other recalls by Johnson Matthey Inc.

All 2019 recalls